tiprankstipranks
Trending News
More News >
Viemed Healthcare US (VMD)
NASDAQ:VMD
US Market

Viemed Healthcare (VMD) Earnings Dates, Call Summary & Reports

Compare
168 Followers

Earnings Data

Report Date
May 11, 2026
TBA (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
0.09
Last Year’s EPS
0.06
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Mar 04, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presents a predominantly positive outlook: Viemed delivered record revenue and adjusted EBITDA, materially improved free cash flow, diversified its revenue mix with strong growth in sleep and resupply, and closed an accretive maternal health acquisition. The company acknowledges near-term headwinds from the implementation of the updated NCD—causing short-term moderation in ventilator growth, additional compliance effort, and an expected flat Q1 cadence—but emphasizes that these are transition-related and that early 2026 signals (strong January vent setups, ALJ appeals success) indicate improvement. Financial position (low net leverage, liquidity) and a disciplined capital allocation plan (including buybacks) underpin confidence in the growth plan, making the positives outweigh the transition-related negatives.
Company Guidance
Viemed guided 2026 net revenue of $310–$320 million (midpoint ≈17% year‑over‑year ex‑acquisitions) and adjusted EBITDA of $65–$69 million (noting 2025 adjusted EBITDA was a record $61.4M, 22.7% margin, and included a $2.2M one‑time vent buyback gain); management expects an uneven quarterly cadence—Q1 flat to slightly down sequentially, then roughly 3%–5% sequential growth beginning in Q2—while maintaining stable margins and reinvesting in technology/compliance, targeting net CapEx of ~10%–11.5% of revenue in 2026. For context, 2025 revenue was $270.3M (Q4 $76.2M), gross margin was just under 58%, free cash flow improved to $28.1M (vs. $11.6M in 2024) on $51.9M net cash from operations and ~$23.8M net CapEx (Q4 FCF $10.8M), equipment & supply sales grew ~$19.4M (~63% YoY), ventilator rentals rose ~$12.2M (~10%), non‑vent HME rentals increased ~$9.7M (~20%), services revenue grew ~$4.8M (~24%), PATH therapy patients reached 34,528 (+62% YoY), new sleep setups rose 70% in 2025, resupply patients totaled 36,561 (+49% YoY); balance sheet liquidity includes $13.5M cash, ~$46M available on credit, long‑term debt $11.3M (effectively no net debt), and the board authorized a 2026 share repurchase program after buying back 5% of shares at an average $6.69.
Record Revenue and Adjusted EBITDA
Full-year 2025 revenue of $270.3M, up ~21% YoY; Q4 revenue $76.2M, up 26% YoY. Record adjusted EBITDA of $61.4M for 2025 with a margin of ~22.7%; Q4 adjusted EBITDA of $18.2M.
Strong Free Cash Flow and Cash Generation
Net cash provided by operating activities of $51.9M in 2025. Free cash flow totaled $28.1M (vs $11.6M in 2024), more than doubling year over year; Q4 free cash flow $10.8M. Net cash of $13.5M and $46M available under credit facilities with long-term debt of $11.3M (effectively no net debt).
Rapid Growth in Sleep and Resupply
PATH therapy patient count reached 34,528 as of 12/31/2025, +62% YoY. New sleep patient setups increased 70% in 2025. Resupply patients totaled 36,561, up 49% YoY. Sleep increased from 16% to 20% of revenue year-over-year.
Diversification of Revenue Mix
Ventilation contribution declined from 56% to 51% of revenue as other categories scaled. Equipment and supply sales increased ~$19.4M (~63% YoY). Ventilator rentals increased ~$12.2M (~10% YoY). Other non-vent HME rentals +$9.7M (~20% YoY); services revenue +$4.8M (~24% YoY). Maternal health contributed ~3% of 2025 revenue (~$9.0M).
Accretive Acquisition and New Growth Engine
Lehan’s Medical Equipment acquisition (closed July 1) integrated smoothly and was accretive immediately, producing positive net income contribution in both quarters post-close. Maternal health generated ~$9M of revenue in 2025 and is positioned for scalable expansion.
Operational and Regulatory Strength
Company reports strong compliance/documentation capabilities: 100% success rate at the ALJ level on appealed Medicare Advantage denials under the new NCD and earlier resolution of denials. January 2026 was one of the strongest months for new ventilator setups in company history.
Prudent Capital Allocation
Board authorized a new share repurchase program for 2026 after buying back 5% of outstanding shares at an average price of $6.69 in 2025. Guidance for 2026: revenue $310M–$320M (midpoint ~17% YoY) and adjusted EBITDA $65M–$69M.

Viemed Healthcare (VMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

VMD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 11, 2026
2026 (Q1)
0.09 / -
0.06
Mar 04, 2026
2025 (Q4)
0.13 / 0.14
0.140.00% (+0.04)
Nov 05, 2025
2025 (Q3)
0.09 / 0.09
0.1-10.00% (-0.01)
Aug 06, 2025
2025 (Q2)
0.09 / 0.08
0.04100.00% (+0.04)
May 07, 2025
2025 (Q1)
0.06 / 0.06
0.0450.00% (+0.02)
Mar 10, 2025
2024 (Q4)
0.10 / 0.10
0.0911.11% (+0.01)
Nov 06, 2024
2024 (Q3)
0.07 / 0.10
0.0742.86% (+0.03)
Aug 07, 2024
2024 (Q2)
0.07 / 0.04
0.06-33.33% (-0.02)
May 06, 2024
2024 (Q1)
0.07 / 0.04
0.040.00% (0.00)
Mar 06, 2024
2023 (Q4)
0.10 / 0.09
0.0650.00% (+0.03)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

VMD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 04, 2026
$9.08$8.40-7.49%
Nov 05, 2025
$6.43$6.26-2.64%
Aug 06, 2025
$6.45$6.96+7.91%
May 07, 2025
$7.27$6.42-11.69%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Viemed Healthcare US (VMD) report earnings?
Viemed Healthcare US (VMD) is schdueled to report earning on May 11, 2026, TBA (Confirmed).
    What is Viemed Healthcare US (VMD) earnings time?
    Viemed Healthcare US (VMD) earnings time is at May 11, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is VMD EPS forecast?
          VMD EPS forecast for the fiscal quarter 2026 (Q1) is 0.09.

            Viemed Healthcare (VMD) Earnings News

            Viemed Healthcare Stock Finishes 14.2% Lower on Earnings Miss
            Premium
            Market News
            Viemed Healthcare Stock Finishes 14.2% Lower on Earnings Miss
            4y ago